AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00005822
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT02135016
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
Trial: NCT04595929
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes
Trial: NCT04595929
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy according to indications.
Trial: NCT01398657
Drug: Adjuvant Androgen-Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-term adjuvant androgen-deprivation therapy
Trial: NCT01088711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly placebo capsule
Trial: NCT03743727
Drug: Combined therapy LDV and SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
Trial: NCT00355771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet OD in the morning for 8 weeks
Trial: NCT02561546
Drug: p53 gene therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
Trial: NCT02561546
Drug: Trans-catheter embolization
RxNorm normalized name: HOSE ANTI-EMBOLISM CALF LEN LARGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-catheter embolization alone
Trial: NCT00664365
Drug: GSK958108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
Trial: NCT00664365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
Trial: NCT00030966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo monthly infusion for up to 116 weeks.
Trial: NCT01442649
Drug: 5-fluoro-uracil
RxNorm normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Trial: NCT00568217
Drug: Diclofenac, Paracetamol, Ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
Trial: NCT02508103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
Trial: NCT01293747
Drug: Estradiol + Progesterone
RxNorm normalized name: ESTRADIOL/PROGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
Trial: NCT01293747
Drug: Estradiol + Progesterone
RxNorm normalized name: ESTRADIOL/PROGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
Trial: NCT02906579
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02906579
Drug: IW-1973
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01481883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily for 12 week trial
Trial: NCT04301739
Drug: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapeutics
Trial: NCT04301739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03615820
Drug: Niosomal PPE oromucoadhesive film
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
Trial: NCT03615820
Drug: Oromucoadhesive film
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oromucoadhesive film without PPE control testing which represents Placebo group
Trial: NCT00004763
Drug: Ethinyl estradiol/norethindrone
RxNorm normalized name: ETHINYL ESTRADIOL/NORETHINDRONE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02028780
Drug: Placebo to dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03457324
Drug: JCM-16021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This prescription with seven ingredients.
Trial: NCT03457324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01602679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Trial: NCT02966717
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
Trial: NCT02112019
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00806208
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.012 mg/kg MEDI 507 and Methylprednisolone
Trial: NCT00806208
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg MEDI 507 and Methylprednisolone
Trial: NCT00806208
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg MEDI 507 and Methylprednisolone
Trial: NCT00806208
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg MEDI 507 and Methylprednisolone
Trial: NCT01427270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match OXN or OXY taken orally every 12 hours
Trial: NCT00421109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated tablet. Once daily for 28 days
Trial: NCT02033278
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion plus conventional medical treatment (as indicated by clinician)
Trial: NCT00560482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical appearing gelatin capsules containing placebo
Trial: NCT01563913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill, taken for 1.5 years
Trial: NCT04388124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01817166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Trial: NCT03942887
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
Trial: NCT03058471
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
Trial: NCT03058471
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
Trial: NCT00003032
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04462822
Drug: ADVAIR DISKUS® 250/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT01014078
Drug: Azithromycin Ophthalmic Solution, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
Trial: NCT01014078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
Trial: NCT01089010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo in capsules administered as a single oral dose.
Trial: NCT02589847
Drug: Standard of Care Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Antibiotics
Trial: NCT02970539
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
Trial: NCT02023112
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Trial: NCT00050479
Drug: Celecoxib (Celebrex)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04035538
Drug: CKD-320, D012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
Trial: NCT01293084
Drug: 7% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mL 7% saline inhaled once over 20 minutes
Trial: NCT03147599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01124799
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
Trial: NCT01124799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo dose in the morning, at noon and in the evening, for 9 days
Trial: NCT04499196
Drug: GlucoCorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administering glucocorticoid
Trial: NCT00791037
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02258906
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03001323
Drug: Standard long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.
Trial: NCT00718523
Drug: AMG 479 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered Day 1 of each 21 day cycle.
Trial: NCT00877539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, two doses 4 hours apart
Trial: NCT02080364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally, once daily for 18 months
Trial: NCT02762708
Drug: Exendin-9,39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.
Trial: NCT02762708
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.
Trial: NCT01568112
Drug: BG00012 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BG00012
Trial: NCT00784589
Drug: General Corticotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
Trial: NCT00624832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
Trial: NCT04274075
Drug: GDC-9545 Tablet, Fasted: Treatment A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
Trial: NCT04274075
Drug: GDC-9545 Capsule, Fasted: Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
Trial: NCT04274075
Drug: GDC-9545 Capsule, Fed: Treatment C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
Trial: NCT01269099
Drug: IV-PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
Trial: NCT03181685
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation (COS)
Trial: NCT02217852
Drug: Captopril,Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
Trial: NCT02217852
Drug: Beijing hypotensive No.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
Trial: NCT04464408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
Trial: NCT02588092
Drug: ADCT-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00423813
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT00423813
Drug: Xyrem®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two doses
Trial: NCT00869128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03731390
Drug: GR1405 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
Trial: NCT01064362
Drug: Low molecular weight heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
Trial: NCT00005802
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005802
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00717652
Drug: arbutin, tretinoin, triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arbutin, tretinoin, triamcinolone
Trial: NCT00717652
Drug: Triluma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinone, Fluoncinolone, Tretinoin
Trial: NCT03510897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isotonic saline
Trial: NCT00729300
Drug: disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg daily
Trial: NCT00774072
Drug: Tobramycin (Gernebcin®)
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 ml / day in each nostril
Trial: NCT00615810
Drug: Kivexa plus Sustiva
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label once daily for oral administration
Trial: NCT00352625
Drug: Ketoprofen Topical Patch 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03364036
Drug: Mavenclad®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Trial: NCT00565201
Drug: Placebo and rehab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
Trial: NCT00734656
Drug: dutasteride + ethanol
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
Trial: NCT00734656
Drug: placebo medication + ethanol
RxNorm normalized name: ethanol Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
Trial: NCT00734656
Drug: placebo medication + placebo alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
Trial: NCT01471444
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
Trial: NCT01677182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets for sublingual administration
Trial: NCT02632370
Drug: Gliolan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
Trial: NCT01400906
Drug: lactose powder
RxNorm normalized name: Lactose Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose powder in dry powder device : placebo comparator
Trial: NCT01041274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth daily for 12 months.